Etrolizumab
Humanized (from rat) | |
|---|---|
| Target | β7 subunit of α4β7 and αEβ7 integrin heterodimers |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6396H9874N1702O2010S42 |
| Molar mass | 144119.77 g·mol−1 |
  (what is this?) (verify) | |
Etrolizumab (rhuMAb Beta7) is a
β7 subunit of integrins α4β7 and αEβ7.[1] Etrolizumab was developed by Genentech[2][3] by engineering the FIB504 antibody to include human IgGl-heavy chain and κ-light chain frameworks; it is manufactured in CHO cells.[4]
As of 2016, it was in phase III studies for induction and maintenance therapy in people with ulcerative colitis and Crohn's.[2][5][6] According to data of one meta-analysis efficacy of Etrolizumab is comparable with conventional therapies such as Infliximab with less adverse events [7]
Phase III clinical trials produced mixed results; and, on October 14, 2020,
Hoffmann-La Roche, the parent company of Genentech, abandoned further efforts to develop etrolizumab for ulcerative colitis, but continued development for Crohn's disease, [8] until disappointing trial results led to this being abandoned too in Feb 2022. [9]
References
- ^ Adis Insight Etrolizumab Archived 2016-06-03 at the Wayback Machine Latest Information Update: 16 Dec 2015
- ^ a b UK Medicines Information. etrolizumab at UKMI Archived 2016-06-04 at the Wayback Machine Page accessed May 10, 2016
- ^ "Genentech: Our Pipeline". www.gene.com. Archived from the original on 2020-05-24. Retrieved 2020-05-22.
- S2CID 32434092. as referenced in paragraph 146 of the PCT application.
- S2CID 24706213.
- PMID 26630451.
- S2CID 53235342.
- ^ Tong, Amber (October 15, 2020). "Roche writes off ulcerative colitis portion of etrolizumab program, days after dissecting PhIII setback". Endpoints. Archived from the original on 24 November 2020. Retrieved 2 January 2021.
- ^ "Archived copy". Fierce Biotech. Archived from the original on 8 March 2023. Retrieved 8 March 2023.
{{cite web}}: CS1 maint: archived copy as title (link)
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |